NCT05959499

A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fed Conditions in Healthy Adult Volunteers

An Open-label, Randomized, Fed, Single-dose, 2-sequence, 4-period, Full Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is evaluate the pharmacokinetics and safety between single administration of "BR6002" and coadministration of "BR6002A" and "BR6002B" under fed conditions in healthy adult volunteers

Conditions

• Gastric or Duodenal Ulcer

Interventions

Type	Name	Description
DRUG	BR6002A	One tablet administered alone
DRUG	BR6002B	One tablet administered alone
DRUG	BR6002	One capsule administered alone

Timeline

• Start date: 2023-07-13
• Primary completion: 2023-09-12
• Completion: 2023-09-12
• First posted: 2023-07-25
• Last updated: 2023-11-18

Locations

1 site across 1 country: South Korea